Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06270953 · ClinicalTrials.gov registry record
Non-invasive Monitoring: Impact on Patient Management and Outcomes
A clinical trial, sponsored by Turtle Shell Technologies Pvt..
- Completed
- Registry status
- 54
- Enrollment target
NCT06270953: Completed study, sponsored by Turtle Shell Technologies Pvt..
NCT06270953 is a clinical trial that has completed, run by Turtle Shell Technologies Pvt.. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06270953 has completed, sponsored by Turtle Shell Technologies Pvt..
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
Enhancing patient monitoring in SNFs and ALFs is crucial due to challenges in recognizing deteriorating health. Gaps in vital sign checks lead to missed indicators and adverse outcomes. Turtle Shell Technologies' Dozee Pro NX offers continuous non-invasive monitoring, alerting healthcare providers of vital sign changes. This clinical study aims to evaluate Dozee Pro Nx's impact on patient outcomes, practitioner efficiency, and healthcare costs in SNFs and ALFs, addressing gaps in care delivery.
Interventions
- DEVICE Dozee Pro NX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2024-01-19 |
| Est. Completion | 2024-06-30 |
What the finished NCT06270953 record still lists
NCT06270953 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dozee Pro NX is the first listed.
NCT06270953 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06270953 about?
NCT06270953 is a clinical study titled "Non-invasive Monitoring: Impact on Patient Management and Outcomes". Enhancing patient monitoring in SNFs and ALFs is crucial due to challenges in recognizing deteriorating health. Gaps in vital sign checks lead to missed indicators and adverse outcomes. Turtle Shell Technologies' Dozee Pro NX offers continuous non-invasive monitoring, alerting healthcare providers o...
What is the current status of trial NCT06270953?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2024-01-19. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT06270953?
The interventions under investigation include: Dozee Pro NX (DEVICE).
Who is sponsoring clinical trial NCT06270953?
This trial is sponsored by Turtle Shell Technologies Pvt., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI